Exscientia shares are trading higher after the company announced the enrollment of the first patient in the Phase 1/2 "ELUCIDATE" clinical trial assessing GTAEXS617 in advanced solid tumors.
Portfolio Pulse from Benzinga Newsdesk
Exscientia has announced the enrollment of the first patient in the Phase 1/2 'ELUCIDATE' clinical trial assessing GTAEXS617 in advanced solid tumors. This has led to a rise in the company's share prices.
July 10, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exscientia's shares are trading higher following the announcement of the first patient enrollment in the 'ELUCIDATE' clinical trial.
The enrollment of the first patient in the 'ELUCIDATE' clinical trial is a significant milestone for Exscientia. This development indicates progress in the company's research and development efforts, which is a positive signal to investors. As a result, the company's shares are trading higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100